A clinical trial to evaluate the combination of brigatinib with an mTOR inhibitor in NF2-deficient meningiomas is warranted.<h4>Significance</h4>AG-NF2-Men represents the first NF2-SWN-related meningioma model. This evidence concerns the gene ELL and meningioma.